Vericel (NASDAQ:VCEL – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at Canaccord Genuity Group in a report released on Tuesday,Benzinga reports. They currently have a $60.00 target price on the biotechnology company’s stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 7.47% from the company’s previous close. […]

Equities researchers at Canaccord Genuity Group assumed coverage on shares of ARQ (NASDAQ:ARQ – Get Free Report) in a research report issued on Tuesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $10.00 price target on the stock. Canaccord Genuity Group’s target price suggests a potential upside of 31.06% from the stock’s […]

Canaccord Genuity Group restated their buy rating on shares of Seres Therapeutics (NASDAQ:MCRB – Free Report) in a report issued on Thursday morning,Benzinga reports. Canaccord Genuity Group currently has a $10.00 target price on the biotechnology company’s stock. MCRB has been the topic of several other research reports. StockNews.com cut shares of Seres Therapeutics from […]

Passage Bio (NASDAQ:PASG – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Canaccord Genuity Group in a report issued on Thursday,Benzinga reports. They presently have a $13.00 price objective on the stock. Separately, Rodman & Renshaw initiated coverage on shares of Passage Bio in a research report on Tuesday, September […]

Canaccord Genuity Group assumed coverage on shares of CeriBell (NASDAQ:CBLL – Free Report) in a research note issued to investors on Tuesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $30.00 price target on the stock. Several other research firms also recently commented on CBLL. Bank of America assumed coverage on […]